Lenvat 4mg Capsules Lenvat 4 contains Lenvatinib, an oral multiple receptor tyrosine kinase (RTK) inhibitor that selectively targets VEGFR1, VEGFR2, and VEGFR3, along with fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. By inhibiting these signaling pathways, Lenvatinib disrupts vascular endothelial growth factor-mediated tumor angiogenesis, cell proliferation, and oncogenic signaling cascades. Lenvat 4 is indicated for the treatment of progressive, locally advanced, or metastatic differentiated thyroid cancer (DTC), advanced renal cell carcinoma (RCC) in combination with pembrolizumab or everolimus, unresectable hepatocellular carcinoma (HCC), and advanced endometrial carcinoma.